Genfit S.A.
GNFT
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.99
Price-2.92%
-$0.12
1Y
Price
Market Cap
$198.683m
Small
Price/Earnings 3y Avg5y Avg
133x
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$111.554m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
$37.427m
-
1y CAGR-
3y CAGR-
5y CAGREPS
$0.59
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$69.224m
$151.424m
Assets$82.200m
Liabilities$62.133m
DebtDebt to Assets
41.0%
1.4x
Debt to EBITDAFree Cash Flow
-$64.039m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company